MARKET

RCOR-WS

RCOR-WS

Renovacor Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

0.5400
-0.0100
-1.82%
Closed 16:00 01/14 EST
OPEN
0.5500
PREV CLOSE
0.5500
HIGH
0.5609
LOW
0.4999
VOLUME
21.40K
TURNOVER
--
52 WEEK HIGH
1.750
52 WEEK LOW
0.3584
MARKET CAP
--
P/E (TTM)
-2.4479
1D
5D
1M
3M
1Y
5Y
BRIEF-Renovacor Names Elizabeth White As Chief Business Officer And Senior Vice President Of Operations
reuters.com · 07/19/2021 12:40
BRIEF-Renovacor Inc To Merge With Chardan Healthcare Acquisition 2 Corp
reuters.com · 03/23/2021 12:03
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RCOR-WS. Analyze the recent business situations of Renovacor Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About RCOR-WS
Renovacor, Inc., formerly Chardan Healthcare Acquisition 2 Corp., is a preclinical-stage gene therapy company. The Company is engaged in developing a pipeline of adeno-associated virus (AAV)-based gene therapies for Bcl2-associated athanogene 3 (BAG3) gene mutation-associated diseases in areas of unmet medical need. It focuses on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy. Its lead product candidate, REN-001, is an AAV9-based gene therapy designed to treat BAG3-associated dilated cardiomyopathy (DCM).

Webull offers kinds of Renovacor Inc stock information, including AMEX:RCOR WS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCOR WS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RCOR-WS stock methods without spending real money on the virtual paper trading platform.